Biodesix ropes in $12M in Series E financing for blood-based lung cancer Dx

Biodesix CEO David Brunel

Biodesix reeled in an additional $12 million in Series E financing for its blood-based test for non-small cell lung cancer, bringing the company's proceeds from the sale to $27 million. The Boulder, CO-based molecular diagnostic outfit plans to use the funds to ramp up development for its VeriStrat tool, which helps oncologists decide whether to treat advanced lung cancer patients with Roche's ($RHHBY) Tarceva (erlotinib) or traditional chemotherapy. "Securing this investment enables us to effectively bring innovative diagnostics to market that help inform treatment decisions and improve patient care in a cost effective manner," CEO David Brunel said in a statement. More from FierceMedicalDevices

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.